Giuseppe Tisone is Principal Investigator for the Liver Transplant for Hepatocellular Carcinoma
Giuseppe Tisone is Full Professor of Surgery, at the University of Rome-Tor Vergata. The research sectors he has always dealt with, publishing a series of scientific papers and participating in various conferences, also as a speaker, currently mainly concern organ transplants: studies on Tolerance in organ transplants (in this context coordination of studies of national relevance AIFA – Study prospective randomized multicenter to evaluate the clinical benefits of stopping therapy immunosuppressive in liver transplant patients identified as “operationally tolerant” on base of non-invasive tolerance tests and Macro Project Basilicata -CNT- Search for tolerance markers immunological in patients undergoing prospective reduction of immunosuppressive therapy after transplantation of liver or kidney); immunosuppressive therapy in organ transplants with particular attention to new drugs; new techniques of perfusion of the abdominal organs during multi-organ sampling; role of bile acids in liver transplantation; factors capable of influencing the recurrence of hepatitis C after liver transplantation, with particular attention to role of steatosis; role of bile acids in liver transplantation.
Bohne F, et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest. 2012;122(1):368–382.
Lenci I, et al. Tips for TIPS: A combined percutaneous and transjugular approach for intrahepatic portosystemic shunt placement after liver transplant. Ann Hepatol. 2019;S1665-2681(19)32276-8.
Adam R, et al. Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Registry (ELTR): An Extension Study. Transplantation. 2019;103(9):1844–1862.
Manzia TM, et al. A 3-month, Multicenter, Randomized, Open-label Study to Evaluate the Impact on Wound Healing of the Early (vs Delayed) Introduction of Everolimus in De Novo Kidney Transplant Recipients, With a Follow-up Evaluation at 12 Months After Transplant (NEVERWOUND Study). Transplantation. 2020;104(2):374–386.
Firl DJ, et al. Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. Hepatology. 2020;71(2):569–582.